Archives
- 2018-07
- 2019-08
- 2019-09
- 2019-10
- 2019-11
- 2019-12
- 2020-01
- 2020-02
- 2020-03
- 2020-04
- 2020-05
- 2020-06
- 2020-07
- 2020-08
- 2020-09
- 2020-10
- 2020-11
- 2020-12
- 2021-01
- 2021-02
- 2021-03
- 2021-04
- 2021-05
- 2021-06
- 2021-07
- 2021-08
- 2021-09
- 2021-10
- 2021-11
- 2021-12
- 2022-01
- 2022-02
- 2022-03
- 2022-04
- 2022-05
- 2022-06
- 2022-07
- 2022-08
- 2022-09
- 2022-10
- 2022-11
- 2022-12
- 2023-01
- 2023-02
- 2023-03
- 2023-04
- 2023-05
- 2023-06
- 2023-08
- 2023-09
- 2023-10
- 2023-11
- 2023-12
- 2024-01
- 2024-02
- 2024-03
- 2024-04
- 2024-05
- 2024-06
- 2024-07
- 2024-08
- 2024-09
- 2024-10
- 2024-11
- 2024-12
- 2025-01
- 2025-02
- 2025-03
-
DAergic as well as GABAergic
2024-08-21
DAergic, as well as GABAergic and glutamatergic neurons, send projections to target forebrain structures, such as the nucleus accumbens (NAc) and medial prefrontal cortex (mPFC), and support diverse functional roles (Carr and Sesack, 2000a, Carr and Sesack, 2000b, Omelchenko and Sesack, 2009, Taylor
-
Further evidence for action mechanism was provided by assays
2024-08-21
Further evidence for action mechanism was provided by assays using [3H]nisoxetine, a selective NET inhibitor used as standard radioligand for competitive binding experiments. The results showed dose-dependent blocking of [3H]nisoxetine binding by both xylazine and dexmedetomidine. Nisoxetine binds t
-
Adiponectin belongs to the CTRP C q TNF related protein
2024-08-21
Adiponectin belongs to the CTRP (C1q/TNF-related protein) superfamily. Except for adiponectin, 15 additional members have been identified (CTRP1-15) (Schaffler and Buechler, 2012). Of all the CTRPs, CTRP9 has the highest identity to adiponectin in globular domain (Wong et al., 2009). The structure o
-
br Discussion The clinical course of our patient until May
2024-08-21
Discussion The clinical course of our patient until May 2012 was rather typical of early onset AChR-MG. Later on, the pattern of the disease was more typical of MuSK-MG, as evidenced by the distribution of myasthenic weakness and the unprovoked exacerbations. The EPZ004777 of MuSK-MG appears to
-
In addition to the data provided by the
2024-08-21
In addition to the data provided by the Ki16425 treatment in the K/BxN arthritis model, new findings from the study of two new LPA receptor antagonists confirm the involvement of the LPA pathway in the pathogenesis of experimental arthritis. In the study by Miyabe et al., the authors reported the tr
-
br The future of cancer therapeutics with
2024-08-21
The future of cancer therapeutics with Aurora kinase inhibitors Involvement of Aurora kinases in deregulating multiple tumor suppressor and oncogenic pathways together with the preclinical findings on the efficacy of Aurora kinase inhibitors in attenuating growth of tumor Fungicidin suggests tha
-
The ambiguity surrounding the role played
2024-08-21
The ambiguity surrounding the role played by the 15-LOXs in malignant biological processes stems also from the limitations of current animal models, and especially the usage of its 12/15-LOX murine homolog, which can also catalyze the production of 12-HETE. Indeed, the proinflammatory effect of 12-H
-
br Experimental protocols br Results and discussion
2024-08-21
Experimental protocols Results and discussion Conclusion 15-LOX-1 is an important mammalian lipoxygenase which plays an important role in the biosynthesis of leukotrienes, lipoxins and other signalling molecules. These signalling molecules play a regulatory role in several respiratory disea
-
The most likely explanation for the species differences in
2024-08-20
The most likely explanation for the species differences in aromatase distribution and the unique Oseltamivir acid distribution in humans is the unique location, size and highly elaborate organization of the human aromatase gene (e.g. Bulun et al., 2003). The human Cyp19 is a large gene located on c
-
br ROS in AiP and regeneration Tissue wounding and
2024-08-20
ROS in AiP and regeneration Tissue wounding and inflammation are associated with production of ROS, and recent studies show that generation of ROS, especially during the initial stages of wounding and regeneration are essential for an efficient wound healing response. ROS, in particular H2O2 func
-
In spite of this unexpectedly after
2024-08-20
In spite of this, unexpectedly, after three-week cherry puree consumption no AC increase was observed, irrespective of the method used (Table 2). A statistically significant decrease of AC was even measured by LOX-FL and ORAC methods (−3.5% and −9%, respectively). Nevertheless, a much more evident d
-
Second the choice of the PAABD is critical
2024-08-20
Second, the choice of the PAABD is critical for an efficient and sensitive biosensor. The sequence of the PAABD should present high affinity and efficient recognition of the phosphorylated substrate, as opposed to poor affinity for the unphosphorylated substrate, and should display a fully reversibl
-
br Introduction Nonalcoholic fatty liver disease NAFLD is
2024-08-20
Introduction Nonalcoholic fatty liver disease (NAFLD) is a clinicopathologic spectrum of liver pathologies associated with excessive accumulation of fat in the liver. This spectrum is continuous but can be graded based on pathological features; in increasing severity, these are: bland steatosis,
-
Flubendazole australia We recently identified a G A dependen
2024-08-20
We recently identified a G9A-dependent epigenetic mechanism for transcriptional activation of the serine pathway in cancer cells (Ding et al., 2013). G9A, also known as EHMT2 and KMT1C, is a H3K9 methyltransferase that has a primary role in catalyzing H3K9me1 and H3K9me2 in euchromatin (Shinkai and
-
Aldose reductase ALR EC the first
2024-08-20
Aldose reductase (ALR2, EC1.1.1.21), the first enzyme in the polyol pathway, is a monomeric oxidoreductase that catalyses the NADPH-dependent reduction of a wide variety of carbonyl compounds, especially glucose. In this metabolism pathway, glucose is firstly reduced to sorbitol catalyzed by ALR2 wi
14532 records 97/969 page Previous Next First page 上5页 96979899100 下5页 Last page